Entrectinib clinical trials
Also written Rozlytrek, RXDX-101 and RO7102122.
ClinicalTrials.gov finds 47 studies for entrectinib. How that becomes 32 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives entrectinib. Its counts are asked again every night. How drug pages count
- 47Found by its intervention search · See all 47 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 41 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −3
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.NCT03375437 · Screening to refer patients to an entrectinib trial; not given hereReport a problem
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNCT04644315 · A keyword only; the study tests alectinibReport a problem
- Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib ProgressionNCT07199010 · Earlier treatment; taletrectinib is followed after itReport a problem
- 44Give entrectinib to participants
- −6Observe patients on it, or give it outside a trial
- −6Give it beside what is tested
- 32Test it: the count on this site
Get an email when these change. Save the entrectinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Aug 2019 · ROZLYTREK · NDA 212725 (FDA, Drugs@FDA)
- European Union
- 31 Jul 2020 · Rozlytrek · EMEA/H/C/004936 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 3 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 17
Hoffmann-La Roche (9) · Genentech, Inc. (5) · OHSU Knight Cancer Institute (2) · St. Jude Children's Research Hospital (2) · Cancer Research UK (2) · Alliance for Clinical Trials in Oncology (1) · Jules Bordet Institute (1) · Presage Biosciences (1)
Often tested with
Tested in the same studies.
Alectinib (13) · Atezolizumab (9) · Cobimetinib (7) · Vemurafenib (6) · Trastuzumab (6) · Pertuzumab (6) · Olaparib (4) · Niraparib (4)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8, 2 in phase 3
Studies that test entrectinib, phase 3 first.
- Jan 2027A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Phase 3 · Hoffmann-La Roche
- Jun 2027A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 2/3 · Hoffmann-La Roche
- Nov 2026A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2 · Genentech, Inc.
- Dec 2026Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationPhase 2 · Hunan Province Tumor Hospital
- Dec 2026A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerPhase 4 · Fudan University
- Jun 2027Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsPhase 1/2 · Hoffmann-La Roche
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
- Nov 2027Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsPhase 2 · St. Jude Children's Research Hospital
Studies
Open first, then newest update. How each study uses entrectinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 32
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One of many approved drugs matched to tumour alterationsWritten as EntrectinibReport a problem
- Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaNot yet recruitingPhase 2St. Jude Children's Research HospitalNCT07916389Before surgery in infant glioma with NTRK or ROS1 fusionWritten as EntrectinibReport a problem
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsRecruitingPhase 2St. Jude Children's Research HospitalNCT06528691Alone first line in children under 3 with fused brain tumoursWritten as EntrectinibReport a problem
- Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07829744Before and after surgery, in the ROS1 fusion cohortReport a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886One arm, for ROS1 fusion-positive cancersWritten as EntrectinibReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One of two drugs in the NTRK cohort, salivary gland cancerReport a problem
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT05770544Alone in ROS1 fusion-positive cancers, adults and childrenWritten as EntrectinibReport a problem
- A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerRecruitingPhase 4Fudan UniversityNCT06195228One of two drugs for NTRK-altered thyroid cancerReport a problem
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890One ROS1 inhibitor for ROS1 fusion lung cancerReport a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956Off-label in one arm of a precision medicine trialReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One of many approved drugs matched to tumour alterationsWritten as EntrectinibReport a problem
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedPhase 2Hoffmann-La RocheNCT02568267On the US labelAlone in NTRK, ROS1 or ALK fusion-positive solid tumoursWritten as EntrectinibReport a problem
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Genentech, Inc.NCT04302025Before surgery for ROS1 or NTRK lung cancerWritten as EntrectinibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Hoffmann-La RocheNCT05170204Against durvalumab after chemoradiotherapy, ROS1-positive stage IIIWritten as EntrectinibReport a problem
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03994796One arm, for NTRK or ROS1 brain metastasesWritten as EntrectinibReport a problem
- Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaActive, not recruitingPhase 1OHSU Knight Cancer InstituteNCT05396859With oral decitabine in TP53-mutated AMLWritten as EntrectinibReport a problem
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingPhase 1/2Hoffmann-La RocheNCT02650401On the US labelAlone in children with solid or brain tumoursWritten as EntrectinibReport a problem
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845On the US labelCohorts for ROS1 or NTRK fusion tumoursWritten as EntrectinibReport a problem
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552One cohort, for ROS1-positive lung cancerWritten as EntrectinibReport a problem
- A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingPhase 3Hoffmann-La RocheNCT04603807Against crizotinib in ROS1-positive lung cancerWritten as EntrectinibReport a problem
See all 32 studies that test entrectinib →
Behind its US label · 4 — the studies the FDA label of ROZLYTREK describes
From the Clinical Studies section of ROZLYTREK (2026-10), as openFDA has it. A study the site does not hold is left out.
- Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.CompletedPhase 1Hoffmann-La RocheNCT02097810Report a problem
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedPhase 2Hoffmann-La RocheNCT02568267Report a problem
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingPhase 1/2Hoffmann-La RocheNCT02650401Report a problem
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Report a problem
Tested on its own · 7 — no other medicine in its arm
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT05770544Alone in ROS1 fusion-positive cancers, adults and childrenWritten as EntrectinibReport a problem
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedPhase 2Hoffmann-La RocheNCT02568267On the US labelAlone in NTRK, ROS1 or ALK fusion-positive solid tumoursWritten as EntrectinibReport a problem
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingPhase 1/2Hoffmann-La RocheNCT02650401On the US labelAlone in children with solid or brain tumoursWritten as EntrectinibReport a problem
- A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingPhase 3Hoffmann-La RocheNCT04603807Against crizotinib in ROS1-positive lung cancerWritten as EntrectinibReport a problem
- A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic FunctionCompletedPhase 1Hoffmann-La RocheNCT04226833Single dose in people with liver impairmentWritten as entrectinibReport a problem
- Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.CompletedPhase 1Hoffmann-La RocheNCT02097810On the US labelAlone, first dose-finding study in fusion-positive cancersWritten as EntrectinibReport a problem
- A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.CompletedPhase 1Genentech, Inc.NCT03961100New formulations compared in healthy volunteersWritten as Entrectinib 600 mg (T1)Report a problem
Tested with established drugs · 1 — they are given beside it
Tested in a combination · 22 — another drug in the study is under test too
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One of many approved drugs matched to tumour alterationsWritten as EntrectinibReport a problem
- Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaNot yet recruitingPhase 2St. Jude Children's Research HospitalNCT07916389Before surgery in infant glioma with NTRK or ROS1 fusionWritten as EntrectinibReport a problem
- Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07829744Before and after surgery, in the ROS1 fusion cohortReport a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886One arm, for ROS1 fusion-positive cancersWritten as EntrectinibReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One of two drugs in the NTRK cohort, salivary gland cancerReport a problem
- A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerRecruitingPhase 4Fudan UniversityNCT06195228One of two drugs for NTRK-altered thyroid cancerReport a problem
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890One ROS1 inhibitor for ROS1 fusion lung cancerReport a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956Off-label in one arm of a precision medicine trialReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One of many approved drugs matched to tumour alterationsWritten as EntrectinibReport a problem
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Genentech, Inc.NCT04302025Before surgery for ROS1 or NTRK lung cancerWritten as EntrectinibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Hoffmann-La RocheNCT05170204Against durvalumab after chemoradiotherapy, ROS1-positive stage IIIWritten as EntrectinibReport a problem
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03994796One arm, for NTRK or ROS1 brain metastasesWritten as EntrectinibReport a problem
- Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaActive, not recruitingPhase 1OHSU Knight Cancer InstituteNCT05396859With oral decitabine in TP53-mutated AMLWritten as EntrectinibReport a problem
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845On the US labelCohorts for ROS1 or NTRK fusion tumoursWritten as EntrectinibReport a problem
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552One cohort, for ROS1-positive lung cancerWritten as EntrectinibReport a problem
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedPhase 2Genentech, Inc.NCT04632992One arm, for ROS1 fusion tumoursWritten as EntrectinibReport a problem
- Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Active, not recruitingPhase 2Jules Bordet InstituteNCT04551495With letrozole before surgery in lobular breast cancerWritten as EntrectinibReport a problem
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnEarly Phase 1OHSU Knight Cancer InstituteNCT05238831One possible drug a tumour board can chooseWritten as EntrectinibReport a problem
- Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal MelanomaTerminatedPhase 1/2Arkadiusz Z. Dudek, MDNCT04589832With PAC-1 in metastatic uveal melanomaWritten as EntrectinibReport a problem
- Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue SarcomaCompletedPhase 1Presage BiosciencesNCT03056599One of many drugs microinjected into sarcoma before surgeryReport a problem
Showing 20 of 22. See all 22 →
Beside supportive care · 1 — a supportive treatment or test is studied
One option of several · 5 — a test or a strategy chooses among drugs
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086In every armOne drug the organoid test can chooseWritten as EntrectinibReport a problem
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491One drug the organoid test can chooseWritten as EntrectinibReport a problem
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedPhase 2Hoffmann-La RocheNCT03498521One matched option in the targeted arm, against chemotherapyWritten as EntrectinibReport a problem
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524In every armOne drug the tumour testing can choose for a combinationWritten as EntrectinibReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One option in the tailored-therapy arm, against standard careWritten as EntrectinibReport a problem
Observed · 6 — patients on it are followed, or it is given outside a trial
- Study on the Mechanism of Acquired Resistance of EntrectinibRecruitingFudan UniversityNCT07199959First-line treatment; resistance studied in bloodWritten as EntrectinibReport a problem
- Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCNot yet recruitingNational Cancer Center, ChinaNCT06694129Treatment in practice for ROS1-positive lung cancerWritten as EntrectinibReport a problem
- KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIActive, not recruitingSeoul National University Bundang HospitalNCT05525858One matched drug in a molecular profiling programmeWritten as EntrectinibReport a problem
- Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung AdenocarcinomaCompletedPeking University Cancer Hospital & InstituteNCT07700836One ROS1 inhibitor taken before surgery, looked back onReport a problem
- A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.CompletedPfizerNCT05834348One of many lung cancer drugs in Norwegian practiceWritten as entrectinibReport a problem
- Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene FusionsNo longer availableHoffmann-La RocheNCT03066661Expanded access for fusion-positive cancersWritten as EntrectinibReport a problem
What changed recently
From the registry's own updates since Oct 19, 2026.
Results posted1
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesOct 30, 2026NCT03994796
Newly registered1
- Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaNov 4, 2026NCT07916389
Codes
What other systems call entrectinib · ClinicalTrials.gg INT000452
- MeSH (NLM) C000607349entrectinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) L5ORF0AN1IENTRECTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2197862One source FDA
- Wikidata Q25323953entrectinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114984EntrectinibOne source FDA
- DrugBank DB11986One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607349 | entrectinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | L5ORF0AN1I | ENTRECTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2197862 | — | One source FDA |
| Wikidata | Q25323953 | entrectinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114984 | Entrectinib | One source FDA |
| DrugBank | DB11986 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.